Mucin gene and antigen expression in biliopancreatic carcinogenesis

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Kim, Young S ^a,b   Gum Jr , J R ^a   Crawley, S C ^a   Deng, G ^a   Ho, J J L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Carcinogenesis; Mucin antigen; Mucin gene

Indexed keywords

CARBOHYDRATE; EPITOPE; GLYCOPROTEIN; MUCIN;

ANTIGEN EXPRESSION; BILE DUCT CANCER; CARCINOGENESIS; CONFERENCE PAPER; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0032791918     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S51     Document Type: Conference Paper

References (31)

1. Kim YS, Gum JR, Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconjugate J., 13:693-707, 1996.
2. Kim YS. Mucin glycoproteins in gastrointestinal malignancy and metastasis. Eur. J. Gastroenterology & Hepalology, 5:219-25, 1993.
3. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Path. Int., 47:813-30, 1997.
4. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconjugate J., 14:569-76, 1997.
5. Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim. Biophys. Acta, 1241:407-24, 1995.
6. Gum JR, Hicks JW, Toribara NW et al. Molecular cloning of human intestinal mucin (MUC2) cDNA: identification of the amino terminus and overall sequence similarity to Pre-Pro-von Willebrand factor. J. Biol. Chem., 269:2440-6, 1994.
7. Gum JR_ Jr., Ho JJL, Pratt WS et al. MUC3 human intestinal mucin: analysis of gene structure, the carboxyl terminus and a novel upstream repetitive region. J. Biol. Chem., 272:26678-86, 1997.
8. Carraway CAC, Carraway KL, Komatsu M. Sialomucin/growth factor complex (ASGP-1/ASGP-2) as a potentiator of neuregulin signaling through ErbB2 and ErbB3. In: 5th International Workshop on Carcinoma-associated Mucins. 1998.
9. Vinall LE, Hill AS, Pigny P et al. Variable number tandem repeat polymorphism of the mucin genes located in the complex on 11p15.5. Hum. Genet., 102:357-66, 1998.
10. Chang S-K, Dohrman AF, Basbaum CB et al. Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. Gastroenterology, 107:28-36, 1994.
11. Toribara NW, Roberton AM, Ho SB et al. Human gastric mucin: Identification of a unique species by expression cloning. J. Biol. Chem., 268:5879-85, 1993.
12. Balagé C, Gambús G, Carrato C et al. Altered expression of MUC2, MUC4, and MUC5 mucin genes in pancreas cancer cell lines and tissues. Gastroenterology, 106:1054-61, 1994.
13. Itzkowitz SH, Kjeldsen T, Friera A et al. Expression of sialosyl Tn, and T antigens in human pancreas. Gastroenterology, 100:1691-1700, 1991.
14. y antigen expression in human pancreatic cancer. Cancer Res., 48:475-82, 1988.
15. Chung YS, Ho JJL, Kim YS et al. Detection of human pancreatic cancer associated antigen (SPan-1) in serum of cancer patients. Cancer, 60:163643, 1987.
16. Ho JJL, Bi N, Van P-S et al. Characterization of new pancreatic cancer-reactive monoclonal antibodies directed against purified mucin. Cancer Res., 51:372-80, 1991.
17. 111In-labeled monoclonal antibody Nd2. Antibody Immunoconjugates and Radiopharmaceuticals, 4:493-9, 1991.
18. 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer. Jpn. J. Cancer Res., 88:427-34, 1997.
19. Sawada T, Ho JJL, Chung Y-S et al. E-Selectin binding by pancreatic tumor cells is inhibited by cancer sera. Int. J. Cancer, 57:901-7, 1994.
20. Bresalier RS, Ho SB, Shoeppner HL et al. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology, 110:1354-67, 1996.
21. Yonezawa S, Sueyoshi K, Nomoto M et al. MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of lhe pancreas and liver: its close relationship with prognosis of the patients. Human Pathology, 28:344-52, 1997.
22. Hanski C, Riede E, Gratchev A et al. MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation. Lab. Invest., 77:685-95, 1997.
23. Ligtenberg MJ, Buijs F, Vos HL et al. Suppression of cellular aggregation by high levels of episialin. Cancer Res., 52:2318-24, 1992.
24. Carraway KL, Komatsu M, Carraway CAC. Sialomucin complex (ASGP-1/ASGP-2) effects on adhesion and metastasis. In: 5th International Workshop on Carcinoma-associated Mucins. 1998.
25. Taylor-Papadimitriou J, Stewart L, Burchell J et al. The polymorphic epithelial mucin as a target for immunotherapy. Ann. NY Acad. Sci., 690:69-79, 1993.
26. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J. Immunol., 151(3): 1654-62, 1993.
27. Horan Hand P, Kashmiri SVS, Schlom J. Potential for recombinant immunoglobulin constructs in the management of carcinoma. Cancer, 78:1105-13, 1994.
28. 131I-labeled monoclonal antibody Nd2 in xenografted nude mice. Jap. J. Cancer Res., 87:977-84, 1996.
29. Kondo Y, Chung Y-S, Sawada T et al. Intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts. Jap. J. Cancer Res., 86:1072-9, 1995.
30. Chen L, Chen D, Manome Y et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest., 96:2775-82, 1995.
31. Ring CJ, Blouin P, Martin LA et al. Use of transcriptional regulatory elements of the MUC1 and ERbB2 genes to drive tumour-selective expression of a prodrug activating enzyme. Gene Therapy, 4:1045-52, 1997.